In a 4 January 2016 article published by leading US industry magazine Pharmaceutical Executive Global Direct Gulce Belgin and new Proceutica adviser Donald Macarthur describe how there is more than one route to reach rare disease patients in Turkey with new orphan drugs.’
Donald Macarthur has joined Proceutica on a part-time basis as Adviser. Donald has long been recognised in the pharmaceutical industry as a market access expert on many countries, especially across Europe and parts of Asia.
Proceutica attended XIII.National Metabolic Diseases and Nutrition Congress which took place in Adana on 14-18 April 2015 with a poster : "Is it a Rare Occurance to Gain Access to Orphan Drugs in Turkey?".
Named-patient use can offer orphan drugs access to the Turkish market despite an overall environment that is focused on cost containment, Proceutica Director Gülce Belgin told at the Orphan Drugs Summit 2015 in Copenhagen, Denmark.